AntriaBio

Investors

Press Releases

Dec 28, 2020 Rezolute Announces Change of Transfer Agent
Dec 3, 2020 FDA Clears Rezolute’s IND Application for RZ402
Nov 19, 2020 Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 5, 2020 Rezolute Announces Uplisting to the Nasdaq Capital Market
Oct 9, 2020 Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq
Sep 10, 2020 Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors
Jul 27, 2020 Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism
Jun 15, 2020 Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science
Jun 10, 2020 Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
Jun 1, 2020 Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting

Show All